Group Medical Visits for Patients With Dyslipidemia
ConditionDyslipidemias
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorUniversité de Sherbrooke
About this trial
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L
Disqualifiers
Patients unable to participate in GMV sessions or to provide informed consent
Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months)
A diagnosis of terminal illness or a life expectancy of less than 12 months
Trial design
Design model
Parallel
Treatments tested in this trial
Group medical visits
BehavioralGroup medical visits are designed to improve knowledge of participants and promote self-management.
Treatment groups
288 Participants
are divided into 2 treatment groupsGroup A: Intervention groupExperimental treatment 1 intervention
Group B: Usual care groupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Lipid profile
Low-Density Lipoprotein; High-Density Lipoprotein; Total cholesterol; Triglycerides
Time frame
12 monthsSecondary outcomes
1
Recruitment proportion
Proportion of patients invited to participate in GMVs who actually take part;
Time frame
12 months2
Representativeness of eligible patients
Comparision of sociodemographic data among patients recruited and those representative of the target population
Time frame
12 months3
Attitudes of health professionals towards GMVs
Health professionnals perceptions related to GMVs and to their ability to deliver GMVs. This is assessed through 10 items asking professionals to rate their level of confidence on a 0 to 100% scale raled to their: motivation to recommend GMVs; likelihood to recommend; confidence in discussing it with patients; confidence it will improve patients' knowledge; confidence it will provide appropriate care; confidence it will improve behaviours; confidence it will improve lipid profile; confidence it will improve primary care access; confidence it will reduce needs for individual appointments; confidence it will reduce risk of developing complications.
Time frame
12 months4
Frequency of access to healthcare
Patients patterns of primary care and emergency health service utilization will be described using data from electronic medical records. This will be summarized as the number of individual primary care and emergency visits per year.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov